Form 4: Outlook Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Robert Charles Jahr, Chief Executive Officer and a Director of Outlook Therapeutics, Inc., received 100,000 shares of common stock on July 21, 2026.
Summary
- Grant/award: acquired 100,000 Stock Option (Right to Buy) on July 21, 2026; holds 100,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Robert Charles Jahr — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Grant/award | Stock Option (Right to Buy) | 100,000 | — | — | 100,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Grant/award (100,000 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., neutral, Robert Charles Jahr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.